Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
View in:
PubMed
subject areas
Antineoplastic Combined Chemotherapy Protocols
Boronic Acids
Combined Modality Therapy
Dexamethasone
Fatigue
Hematologic Diseases
Humans
Multiple Myeloma
Pain
Pyrazines
Remission Induction
Sensation Disorders
Stem Cell Transplantation
Survival Analysis
Thalidomide
Treatment Outcome
authors with profiles
Paul Gerard Guy Richardson, M.B.,B.S.
Kenneth Carl Anderson, M.D.
Robin Marie Joyce, M.D.
Irene Ghobrial, M.D.
Edie A. Weller Toolan, Ph.D.
Noopur Raje, M.D.
Nikhil C Munshi, M.D., M.B.,B.S.
Constantine S Mitsiades, Ph.D., M.D.
Teru Hideshima, Ph.D., M.D.
David E. Avigan, M.D.